 Friday afternoon, the FDA approved Kadmon Holdings Incs NASDAQ: KDMN REZUROCK to treat chronic graft-versus-host disease cGVHD, a serious complication of transplant procedures. Formerly known as belumodsil, the drug is a first-in-class ROCK2 inhibitor and now Kadmons first approved drug. 